Physician profile
Krystal J Massey
NPI 1043630619
$8,823.12
in general payments reported to CMS, 2019-2025
20 companies · $6,757 in 2025
The $6,757 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $146 · 2021: $284 · 2022: $800 · 2023: $415 · 2024: $420 · 2025: $6,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,263 · Food and Beverage: $1,172 · Travel and Lodging: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,262.50 |
| Food and Beverage | $1,171.50 |
| Travel and Lodging | $159.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $6,514.22 | 2021-2025 | Ebglyss, Taltz |
| Abbvie INC. | $868.46 | 2020-2025 | |
| Allergan, INC. | $305.30 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $196.73 | 2022-2025 | |
| Genzyme Corporation | $169.76 | 2021-2025 | |
| Amgen INC. | $167.40 | 2021-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $118.23 | 2021-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Galderma Laboratories, L.P. | $91.52 | 2020-2025 | Nemluvio |
| Janssen Biotech, INC. | $82.24 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $46.70 | 2022 | |
| Leo Pharma INC. | $40.65 | 2022-2023 | Adbry |
| Organogenesis INC. | $33.33 | 2024 | Cygnus Dual |
| E.R. Squibb & Sons, L.L.C. | $21.12 | 2022 | |
| Vyne Pharmaceuticals INC. | $18.71 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $16.18 | 2021 | |
| Pfizer INC. | $15.60 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2022 | |
| Biowound Solutions, INC. | $3.90 | 2025 | Bio-Connekt |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Massey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.